Straube, Sebastian

[["dc.bibliographiccitation.firstpage","386"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","389"],["dc.bibliographiccitation.volume","150"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Eccleston, Christopher"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","Bell, Rae F."],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:40:04Z"],["dc.date.available","2018-11-07T08:40:04Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1016/j.pain.2010.05.011"],["dc.identifier.isi","000281675000008"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19142"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","\"Evidence\" in chronic pain - establishing best practice in the reporting of systematic reviews"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD007076"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","COCHRANE DATABASE OF SYSTEMATIC REVIEWS"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:34:11Z"],["dc.date.available","2018-11-07T08:34:11Z"],["dc.date.issued","2009"],["dc.description.abstract","Background Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is a recently developed antiepileptic drug also used in management of chronic neuropathic pain conditions. Objectives To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain. Search strategy We searched MEDLINE, EMBASE, and CENTRAL to May 2009 for randomised controlled trials (RCTs). Additional studies were identified from the reference lists of retrieved papers and on-line clinical trial databases. Selection criteria Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome. Data collection and analysis Two independent review authors extracted data and assessed trial quality. Numbers-needed-to-treat-to-benefit (NNTs) were calculated, where possible, from dichotomous data for effectiveness, adverse events and study withdrawals. Main results There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain. No studies evaluated pregabalin in chronic nociceptive pain, like arthritis. Pregabalin at doses of 300 mg, 450 mg, and 600 mg daily was effective in patients with postherpetic neuralgia, painful diabetic neuropathy, central neuropathic pain, and fibromyalgia (19 studies, 7003 participants). Pregabalin at 150 mg daily was generally ineffective. Efficacy was demonstrated for dichotomous outcomes equating to moderate or substantial pain relief, alongside lower rates for lack of efficacy discontinuations with increasing dose. The best (lowest) NNT for each condition for at least 50% pain relief over baseline (substantial benefit) for 600 mg pregabalin daily compared with placebo were 3.9 (95% confidence interval 3.1 to 5.1) for postherpetic neuralgia, 5.0 (4.0 to 6.6) for painful diabetic neuropathy, 5.6 (3.5 to 14) for central neuropathic pain, and 11 (7.1 to 21) for fibromyalgia. With 600 mg pregabalin daily somnolence typically occurred in 15% to 25% and dizziness occurred in 27% to 46%. Treatment was discontinued due to adverse events in 18 to 28%. The proportion of participants reporting at least one adverse event was not affected by dose, nor was the number with a serious adverse event, which was not more than with placebo. Higher rates of substantial benefit were found in postherpetic neuralgia and painful diabetic neuropathy than in central neuropathic pain and fibromyalgia. For moderate and substantial benefit on any outcome NNTs for the former were generally six and below for 300 mg and 600 mg daily; for fibromyalgia NNTs were much higher, and generally seven and above. Authors' conclusions Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia. A minority of patients will have substantial benefit with pregabalin, and more will have moderate benefit. Many will have no or trivial benefit, or will discontinue because of adverse events. Individualisation of treatment is needed to maximise pain relief and minimise adverse events. There is no evidence to support the use of pregabalin in acute pain scenarios."],["dc.identifier.doi","10.1002/14651858.CD007076.pub2"],["dc.identifier.isi","000268037500026"],["dc.identifier.pmid","19588419"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17760"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","1469-493X"],["dc.title","Pregabalin for acute and chronic pain in adults"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1541"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","1542"],["dc.bibliographiccitation.volume","153"],["dc.contributor.author","Moore, Andrew"],["dc.contributor.author","McQuay, Henry J."],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Eccleston, Christopher"],["dc.contributor.author","Bell, Rae F."],["dc.contributor.author","Aldington, Dominic"],["dc.contributor.author","Phillips, Ceri J."],["dc.date.accessioned","2018-11-07T09:08:52Z"],["dc.date.available","2018-11-07T09:08:52Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1016/j.pain.2012.04.025"],["dc.identifier.isi","000305423700030"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26128"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Estimate at your peril: Imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses Response"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","982"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","989"],["dc.bibliographiccitation.volume","152"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Paine, Jocelyn"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:56:42Z"],["dc.date.available","2018-11-07T08:56:42Z"],["dc.date.issued","2011"],["dc.description.abstract","We defined response in acute pain trials according to percentage of maximum possible efficacy. Minimum efficacy criteria (MEC) of 0%, or at least 15%, 30%, 50%, and 70% pain relief were used to examine stability over time using total pain relief and summed pain intensity difference (SPID), sex differences, and sensitivity. We used individual patient data from placebo-controlled third molar extraction trials: 4 with single-dose oral etoricoxib 120 mg, and 2 with paracetamol, ibuprofen, and ibuprofen plus paracetamol combinations. With etoricoxib, numbers needed to treat (NNTs) were stable between response levels of at least 15% (MEC15) and 50% pain relief (MEC50), and similar for total pain relief and SPID. NNTs were higher (worse) at extremes of MEC, especially with SPID. Results for women and men were similar. NNTs of lower efficacy treatments (paracetamol 500 and 1000 mg) rose rapidly at higher MEC. NNTs of high efficacy treatments (ibuprofen plus paracetamol combinations) showed greater separation at higher MEC. The highest degree of discrimination between treatments was with MEC50 and MEC70. Etoricoxib 120 mg (NNT for >= 50% maximum 6-hour pain relief 1.7) and ibuprofen 200/400 mg plus paracetamol 500/1000 mg (NNTs 1.5 and 1.6, respectively) produced the lowest (best) NNTs in the dental pain model. Timing of patient request for additional analgesia is an alternative analgesic efficacy outcome measure. (C) 2010 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved."],["dc.identifier.doi","10.1016/j.pain.2010.11.030"],["dc.identifier.isi","000289507500009"],["dc.identifier.pmid","21414722"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23210"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: Examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","265"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","268"],["dc.bibliographiccitation.volume","153"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Eccleston, Christopher"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Aldington, Dominic"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","Bell, Rae F."],["dc.contributor.author","Hamunen, Katri"],["dc.contributor.author","Phillips, Ceri J."],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T09:14:05Z"],["dc.date.available","2018-11-07T09:14:05Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1016/j.pain.2011.10.004"],["dc.identifier.isi","000299319800006"],["dc.identifier.pmid","22055553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27318"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Estimate at your peril: Imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","173"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","176"],["dc.bibliographiccitation.volume","149"],["dc.contributor.author","Moore, R. A."],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","McQuay, Henry J."],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Aldington, Dominic"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","Bell, Rae F."],["dc.contributor.author","Kalso, E."],["dc.contributor.author","Rowbotham, M. C."],["dc.date.accessioned","2018-11-07T08:43:47Z"],["dc.date.available","2018-11-07T08:43:47Z"],["dc.date.issued","2010"],["dc.description.sponsorship","NIHR"],["dc.identifier.doi","10.1016/j.pain.2009.08.007"],["dc.identifier.isi","000276980900006"],["dc.identifier.pmid","19748185"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20054"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Clinical effectiveness: An approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","431"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","434"],["dc.bibliographiccitation.volume","149"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:42:58Z"],["dc.date.available","2018-11-07T08:42:58Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1016/j.pain.2010.02.032"],["dc.identifier.isi","000277804700008"],["dc.identifier.pmid","20304558"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19834"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Chronic low back pain analgesic studies - A methodological minefield"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","360"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","364"],["dc.bibliographiccitation.volume","149"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Paine, Jocelyn"],["dc.contributor.author","Phillips, Ceri J."],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:43:47Z"],["dc.date.available","2018-11-07T08:43:47Z"],["dc.date.issued","2010"],["dc.description.abstract","Chronic pain is associated with a range of other problems, including disturbed sleep, depression, anxiety, fatigue, reduced quality of life, and an inability to work or socialise. We investigated whether good symptom control of pain (using definitions of moderate and substantial benefit) is associated with improvement in other symptoms. Individual patient data from four randomised trials in fibromyalgia (2575 patients) lasting 8-14 weeks were used to calculate percentage pain reduction for each completing patient (1858), divided into one of five groups according to pain reduction, irrespective of treatment: substantial benefit - >= 50% pain reduction; moderate - 30% to <50%; minimal - 15% to <30%; marginal - 0% to <15%; worse - <0% (increased pain intensity). We then calculated change from baseline to end of trial for measures of fatigue, function, sleep, depression, anxiety, ability to work, general health status, and quality-adjusted life year (QALY) gain over a 12-month period. Substantial and moderate pain intensity reductions were associated with statistically significant reduction from baseline by end of trial in all measures, with values by trial end at or approaching normative values. Substantial pain intensity reduction resulted in 0.11 QALYs gained, and moderate pain intensity reduction in 0.07 QALYs gained over a 12-month period. Substantial and moderate pain intensity reduction predicts broad beneficial outcomes and improved quality of life that do not occur without pain relief. Pain intensity reduction is a simple and effective predictor of which patients should continue treatment, and which should discontinue and try an alternative therapy. (C) 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.pain.2010.02.039"],["dc.identifier.isi","000276980900029"],["dc.identifier.pmid","20347225"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20055"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","585"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European Journal of Pain"],["dc.bibliographiccitation.lastpage","591"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Moore, R. A."],["dc.contributor.author","Derry, C. J."],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T09:11:18Z"],["dc.date.available","2018-11-07T09:11:18Z"],["dc.date.issued","2012"],["dc.description.abstract","Fixed-dose combination analgesics are used widely, and available both on prescription and over-the-counter. Combination drugs should provide more analgesia than with any single drug in the combination, but there is no evidence in humans about whether oral combinations have just additive effects, or are synergistic or even subadditive. We suggest that the measured result for the combination would be the summation of the absolute benefit increase (effect of active drug minus effect of placebo) of each component of a combination if effects were (merely) additive, and greater than the sum of the absolute benefits if they were synergistic. We tested measured effects of combination analgesics against the sum of the absolute benefits in acute pain and migraine using meta-analysis where individual components and combinations were tested against placebo in the same trials, and verified the result with meta-analyses where individual components and combinations were tested against placebo in different trials. Results showed that expected numbers needed to treat (NNT) for additive effects were generally within the 95% confidence interval of measured NNTs. This was true for combinations of paracetamol plus ibuprofen and paracetamol plus opioids in acute pain, and naproxen plus sumatriptan in migraine, but not where efficacy was very low or very high, nor combinations of paracetamol plus dextropropoxyphene. There was no evidence of synergy, defined as supra-additive effects."],["dc.identifier.doi","10.1016/j.ejpain.2011.08.009"],["dc.identifier.isi","000305947000013"],["dc.identifier.pmid","22396086"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26691"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley Periodicals, Inc"],["dc.relation.issn","1090-3801"],["dc.title","A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]